VanEck Pharmaceutical ETF (NASDAQ:PPH – Get Free Report) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,360,000 shares, an increase of 26.9% from the October 31st total of 1,860,000 shares. Based on an average trading volume of 194,300 shares, the short-interest ratio is presently 12.1 days.
Hedge Funds Weigh In On VanEck Pharmaceutical ETF
A number of hedge funds and other institutional investors have recently bought and sold shares of PPH. Comerica Bank lifted its stake in shares of VanEck Pharmaceutical ETF by 39.4% in the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock valued at $121,000 after purchasing an additional 378 shares during the period. Cetera Investment Advisers lifted its stake in VanEck Pharmaceutical ETF by 316.1% in the first quarter. Cetera Investment Advisers now owns 26,211 shares of the company’s stock valued at $2,377,000 after buying an additional 19,912 shares during the period. Cetera Advisors LLC bought a new position in VanEck Pharmaceutical ETF during the first quarter worth about $606,000. CWM LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the 2nd quarter worth about $55,000. Finally, Optimum Investment Advisors bought a new stake in shares of VanEck Pharmaceutical ETF in the 2nd quarter valued at about $27,000.
VanEck Pharmaceutical ETF Trading Up 0.1 %
Shares of NASDAQ PPH opened at $90.14 on Monday. VanEck Pharmaceutical ETF has a 1 year low of $77.61 and a 1 year high of $99.51. The firm’s 50-day moving average is $91.95 and its 200-day moving average is $93.03. The firm has a market capitalization of $666.13 million, a PE ratio of 21.04 and a beta of 0.72.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Use the MarketBeat Dividend Calculator
- Contrarian Play: Why Workday Stock Is a Buy After Guidance Cut
- How to Read Stock Charts for Beginners
- Superstores to eCommerce Sales: Walmart Parties Like It’s 1999
- How to Calculate Return on Investment (ROI)
- 3 Green Hydrogen Stocks That May Survive the Trump Chopping Block
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
